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We previously showed that the β-adrenoceptor modulators, clenbuterol and propranolol,
directly blocked voltage-gated sodium channels, whereas salbutamol and nadolol did not
(Desaphy et al., 2003), suggesting the presence of two hydroxyl groups on the aromatic
moiety of the drugs as a molecular requisite for impeding sodium channel block. To ver-
ify such an hypothesis, we synthesized ﬁve new mexiletine analogs by adding one or
two hydroxyl groups to the aryloxy moiety of the sodium channel blocker and tested these
compounds on hNav1.4 channels expressed in HEK293 cells. Concentration–response rela-
tionships were constructed using 25-ms-long depolarizing pulses at −30mV applied from
an holding potential of −120mV at 0.1Hz (tonic block) and 10Hz (use-dependent block)
stimulation frequencies. The half-maximum inhibitory concentrations (IC50) were linearly
correlated to drug lipophilicity: the less lipophilic the drug, minor was the block. The same
compounds were also tested on F1586C and Y1593C hNav1.4 channel mutants, to gain
further information on the molecular interactions of mexiletine with its receptor within the
sodium channel pore. In particular, replacement of Phe1586 and Tyr1593 by non-aromatic
cysteine residues may help in the understanding of the role of π–π or π–cation interactions
in mexiletine binding. Alteration of tonic block suggests that the aryloxy moiety of mexile-
tine may interact either directly or indirectly with Phe1586 in the closed sodium channel
to produce low-afﬁnity binding block, and that this interaction depends on the electrosta-
tic potential of the drug aromatic tail. Alteration of use-dependent block suggests that
addition of hydroxyl groups to the aryloxy moiety may modify high-afﬁnity binding of the
drug amine terminal to Phe1586 through cooperativity between the two pharmacophores,
this effect being mainly related to drug lipophilicity. Mutation of Tyr1593 further impaired
such cooperativity. In conclusion, these results conﬁrm our former hypothesis by showing
that the presence of hydroxyl groups to the aryloxy moiety of mexiletine greatly reduced
sodium channel block, and provide molecular insights into the intimate interaction of local
anesthetics with their receptor.
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INTRODUCTION
Mexiletine is a class Ib antiarrhythmic drug, also considered as
the ﬁrst choice drug for treating myotonic syndromes (Conte
Camerino et al., 2007). Moreover, recent clinical trials demon-
strate its therapeutic value to relieve neuropathic pain (Challapalli
et al., 2005). Mexiletine exerts its pharmacological action through
blockade of voltage-gated sodium channels, thus reducing cell
excitability. Preferential binding to inactivated channels and use-
dependent block are the basis of the selective action of mexiletine
on pathologic hyperactive tissues. The structure of mexiletine is
related to that of local anesthetic (LA) drugs, presenting a pro-
tonable amine group connected to a hydrophobic aromatic ring
through an intermediate ether link (Table 1). We have shown
that little modiﬁcation of these three components can substan-
tially affect sodium channel blockade in vitro and antimyotonic
effects in vivo (Desaphy et al., 1999, 2001; De Luca et al., 2000,
2003, 2004; De Bellis et al., 2006). The use of mexiletine analogs
has allowed to get new important information on the molecu-
lar dynamic interaction between the drug and its receptor within
the sodium channel pore (De Luca et al., 2000, 2003). Besides,
sodium channel mutagenesis experiments have deﬁned the amino
acids most probably involved in the interaction with LAs (Rags-
dale et al., 1994, 1996; Wright et al., 1998; Nau et al., 1999; Wang
et al., 2000; Sunami et al., 2001; Yarov-Yarovoy et al., 2001, 2002;
O’Leary and Chahine, 2002; McNulty et al., 2007; Ahern et al.,
2008).
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Table 1 | Chemical structures and physicochemical properties.
Compound Structure Log P pK a Log D (pH 7.4) Ionization
(mol%, pH 7.4)
Electrostatic potential
(kcal/mol)
Mexiletine 2.21± 0.01 9.28± 0.01 0.53 98.7 −50.3
mHM 1.67± 0.01 9.04± 0.01 0.02 97.7 −48.0
pHM 1.53± 0.01 8.97± 0.01 −0.05 97.3 −50.4
HMM 1.15± 0.01 9.13± 0.01 −0.59 98.1 −64.9
bHMM 0.25± 0.05 9.21± 0.03 −0.85 98.5 −62.6
pHHMM 0.23± 0.02 8.89± 0.02 −1.27 96.8 −65.0
The Log P, pKa, Log D, and electrostatic potential values were determined experimentally, as described in the Section “Materials and Methods.” Values of Log P and
pKa are given as mean±SEM. Ionization of the amine group at pH 7.4 was calculated from Henderson–Hasselbalch equation, Ionization = 1 − 10(pH−pKa ).
In a previous study, we showed that drugs known as modula-
tors of β-adrenergic receptors are able to block sodium channels
in a manner reminiscent of LA drugs (Desaphy et al., 2003).
The β-agonist clenbuterol and the β-blocker propranolol showed
efﬁcacies comparable to mexiletine in producing use-dependent
inhibition of sodium currents in rat skeletal muscle ﬁbers as well
as in tsA201 cells transiently expressing the human muscle sodium
channel isoform, hNav1.4. In contrast, the β-agonist salbutamol
and the β-blocker nadolol had no effect on sodium currents at
1mM concentration. Examination of chemical structures and
physicochemical properties of these drugs revealed the presence of
the two pharmacophores important for sodium channel blocking
activity, the amine group and the aromatic ring, which respec-
tively confer a high pK a and high lipophilicity. However, the two
inactive compounds were characterized by the presence of two
hydroxyl groups on the aromatic moiety, which we proposed to be
determinant for impeding sodium channel blockade.
To verify this hypothesis, we have synthesized new analogs of
mexiletine by introducing one or two hydroxyl groups on the ary-
loxy moiety of the drug and tested them on sodium currents in
mammalian cells permanently transfected with hNav1.4. More-
over site-directed mutagenesis was performed to introduce non-
aromatic cysteine residues in place of the Phe1586 and Tyr1593
residues of hNav1.4, which are thought to be part of the binding
site for LAs within the domain IV segment 6 of sodium channels
(Ragsdale et al., 1994).
The results demonstrate that the presence of hydroxyl groups
on the aromatic moiety drastically reduces the ability of com-
pounds to block sodium channels and provide further insight in
the molecular interaction between LA drugs and their binding site
within the sodium channel pore.
MATERIALS AND METHODS
SITE-DIRECTED MUTAGENESIS AND EXPRESSION OF RECOMBINANT
SODIUM CHANNELS
Full-length cDNA encoding the main α-subunit of wild-type
(WT) skeletal muscle isoform of voltage-gated sodium channel
(hNav1.4) was subcloned in the mammalian expression vector
pRc–CMV. The two hNav1.4 mutants, F1586C and Y1593C, were
engineered by standard two-step PCR-based site-directed muta-
genesis. All PCR reactions were performed using Pfu DNA poly-
merase (Stratagene, La Jolla, CA,USA) for high-ﬁdelity ampliﬁca-
tion (Desaphy et al., 2010). The complete coding region of channel
mutant cDNAs was sequenced to exclude any polymerase errors.
Permanent sodium channel expression was achieved by transfect-
ing 1mgml−1 of plasmid in human embryonic kidney HEK293
cells using the calcium phosphate precipitation method and clone
selection using geneticin (Gibco-Invitrogen, Milan, Italy).
SODIUM CURRENT MEASUREMENT IN HEK293 CELLS
Whole-cell sodium currents (INa) were recorded at room tem-
perature (20–22˚C) using an Axopatch 1D ampliﬁer (Axon
Frontiers in Pharmacology | Pharmacology of Ion Channels and Channelopathies February 2012 | Volume 3 | Article 17 | 2
Desaphy et al. Hydroxylated mexiletine analogs on hNav1.4
Instruments, Union City, CA, USA). Voltage clamp protocols
and data acquisition were performed with pCLAMP 9.2 soft-
ware (Axon Instruments) through a 12-bit A–D/D–A interface
(Digidata 1340, Axon Instruments). Pipettes made with Corning
7052 glass (Garner Glass, Claremont, CA, USA) had resistance
that ranged from 1 to 3MΩ. Currents were low-pass ﬁltered
at 2 kHz (–3 dB) by the four-pole Bessel ﬁlter of the ampli-
ﬁer and digitized at 10–20 kHz. After the patch membrane had
been ruptured, a 25-ms-long test pulse to −30mV from a hold-
ing potential (HP) of −120mV was applied to the cell at a
low frequency until stabilization of INa amplitude and kinet-
ics was achieved (typically 5min). Only those data obtained
from cells exhibiting series resistance errors <5mV were con-
sidered for analysis. Little (<5%) or no rundown was observed
within the experiments. The concentration–response relation-
ships were produced by obtaining the peak current ampli-
tude measured in the presence of drug (IDRUG), normalized to
the peak current amplitude measured in the same cell before
drug application (ICTRL), as a function of drug concentration
[DRUG]. Each data point is the mean± SEM from at least three
cells. The relationships were ﬁtted with a ﬁrst-order binding
function:
IDRUG/ICTRL = Imax/[1 + exp ([DRUG]/IC50)nH] (1)
where IC50 is the half-maximum inhibitory concentration, and nH
is the slope factor. The variable Imax was introduced only for dose–
response relationships of compounds effects on Y1593C channel
mutant at 10Hz, otherwise Imax was ﬁxed to 1.
MUTANT CYCLE ANALYSIS
Mutant cycle analysis was performed to evaluate the cross inﬂu-
ence between amino acid mutations in the hNav1.4 channel
and hydroxyl substitutions in mexiletine, in order to charac-
terize the molecular interactions. The coupling energy ΔG is
thus calculated as RT ·lnΩ, where R is the perfect gas con-
stant (8.314 J Kmol−1), T is the temperature expressed in Kelvin
(295.15 K= 22˚C), and Ω is the coupling constant (Hidalgo and
MacKinnon, 1995).
DRUGS AND SOLUTIONS
Patch clamp pipette solution contained in mM: 120 CsF, 10
CsCl, 10 NaCl, 5 EGTA, and 5 HEPES, and the pH was set
to 7.2 with CsOH. Bath solution for patch clamp recordings
contained (in mM): 150 NaCl, 4 KCl, 2 CaCl2, 1 MgCl2, 5
HEPES, and 5 glucose. The pH was set to 7.4 with NaOH.
Mexiletine hydrochloride [Mex,1-(2,6-dimethylphenoxy)propan-
2-amine] was purchased from Sigma (Milan, Italy). The
hydroxylated analogs of mexiletine {metahydroxymexiletine,
mHM, 3-(2-aminopropoxy)-2,4-dimethylphenol; parahydrox-
ymexiletine, pHM, 4-(2-aminopropoxy)-3,5-dimethylphenol;
hydroxymethylmexiletine, HMM, [2-(2-aminopropoxy)-3-methy
lphenyl]methanol; bis(hydroxymethyl)mexiletine, bHMM, [2-
(2-aminopropoxy)-1,3-phenylene]dimethanol; parahydroxyhy-
droxymethyl mexiletine, pHHMM, 4-(2-aminopropoxy)-3-
(hydroxymethyl)-5-methylphenol} were synthesized in our labo-
ratories (Catalano et al., 2004, 2010; Cavalluzzi et al., 2007). All
drugs were dissolved directly in external patch solution at the
desired ﬁnal concentration. The patched cell was continuously
exposed to a stream of control or drug-supplemented bath
solution ﬂowing out from a plastic capillary.
EXPERIMENTAL DETERMINATION OF DRUG PHYSICOCHEMICAL
PROPERTIES
The pK a and Log P values of mexiletine and its analogs were
determined with a potentiometric method using Sirius GlpK a
(Sirius Analytical Instrument Ltd., Forest Row, East Sussex, UK)
as described previously (Catalano et al., 2010). Because the com-
pounds showed a low water solubility, methanol was used as
co-solvent (methanol–water 10–30% w/w) for the determination
of pK a.
The electrostatic potential of each analogwas determined as the
molecular charge distribution of the corresponding methyl ether
moiety [2,6-dimethylphenyl methyl ether, for Mex; 3-methoxy-
2,4-dimethylphenol, for mHM; 4-methoxy-3,5-dimethylphenol,
for pHM; (2-methoxy-3-methylphenyl)methanol, for HMM; (2-
methoxybenzene-1,3-diyl)dimethanol, for bHMM; 3-(hydroxy
methyl)-4-methoxy-5-methylphenol, for pHHMM] was investi-
gated.Molecularmodels were constructed by fragments offered by
SPARTAN PRO (Wavefunction, Inc., 18401 Von Karman Avenue,
Suite 370, Irvine, CA 92715, USA) inner fragment library and
assuming the suggested default starting geometries. The gen-
erated geometries were optimized by the molecular mechan-
ics MMFF routine proposed by the software and then submit-
ted to a systematic conformer distribution analysis. Conformers
were classiﬁed according to the ab initio gas phase energy con-
tent calculated at the HF/3-21G∗ level. All conformers falling
within a window of 5 kcal/mol above global minimum were
retained. After removal of conformers differing for dihedral val-
ues lower than 10˚, the retained conformers were submitted to
HF/3-21G∗ geometry optimization. The most negative electro-
static potential (i.e., the highest energy of interaction with a
positive charge used as a probe) value for the most stable con-
former of each analog was used for structure–activity relationship
considerations.
RESULTS
EFFECTS OF MEXILETINE AND ANALOGS ON WILD-TYPE hNav1.4
CHANNELS
To compare the effects of mexiletine and its hydroxylated analogs,
block of sodium channels was evaluated by measuring the drug-
induced reduction of INa elicited at −30mV for 25ms every 10
(0.1Hz) or 0.1 (10Hz) s from the HP of −120mV. Applying this
protocol in the absence of drug, there was no signiﬁcant change
in current amplitude for hNav1.4 channels (not shown). Typical
time course of peak INa amplitude during application of 100μM
mexiletine is illustrated in Figure 1A. At the stimulation of 0.1Hz,
application of mexiletine reduced gradually INa down to a plateau.
This block will be called tonic block hereafter. It is due mainly to
the block of closed channels with low afﬁnity, but depends also in
part on the block of closed-state inactivated channels with high
afﬁnity (Desaphy et al., 2001, 2004). Then increasing the stimula-
tion to 10Hz further induced the reduction of INa to a lower level,
determining the so-called use-dependent block, which depends
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FIGURE 1 | Effects of 100μMmexiletine on hNav1.4 currents. (A)Time
course of sodium current amplitude measured in a representative HEK293
cell permanently transfected with hNav1.4 sodium channel subtype before,
during, and after of application of 100μM mexiletine. The sodium current was
elicited by depolarizing the cell membrane to −30mV for 25ms every 10
(0.1Hz) or 0.1 s (10Hz), from a holding potential of −120mV. (B)Typical
sodium current traces are shown, which were obtained from the average of
three records obtained at steady state in absence of drug using 0.1Hz
stimulation frequency (CTRL), and in presence of drug at 0.1Hz (red) and
10Hz (blue).
on the high-afﬁnity binding to inactivated channels. These effects
were fully reversible. Examples of current traces recorded at steady
state before (control) and in the presence of 100μM mexiletine
at 0.1Hz then 10Hz are illustrated in Figure 1B. The reduction
of INa induced by 100μM mexiletine was 32 and 74% at 0.1 and
10Hz, respectively.
The same protocol was used to test all the exploratory com-
pounds at various concentrations. Figure 2 shows representa-
tive current traces recorded at 0.1 and 10Hz stimulation dur-
ing application of 1mM of each compound. Effects of mex-
iletine and mHM were quite similar, blocking INa by 77% at
0.1Hz and 95% at 10Hz. All the other compounds were less
potent than mexiletine, following the rank order of potency:
pHM>HMM> bHMM> pHHMM. The less potent pHHMM
at 1mM had no effect at 0.1Hz and very little effect at 10Hz. All
the effects were fully reversible (not shown). The peak INa ampli-
tude measured in presence of drug at 0.1 or 10Hz was normalized
with respect to control peak INa and reported as a function of drug
concentration to draw concentration–response curves (Figure 3).
All the curves were satisfactorily ﬁtted with a ﬁrst-order bind-
ing function, given the half-maximum inhibitory concentrations
(IC50) reported in Table 2. Addition of one hydroxyl group to
mexiletine had different effects on efﬁcacy depending on the posi-
tion of substituent on the aryloxy moiety, ranging from merely no
effect (mHM) to an eightfold increase of IC50 value (HMM) at
0.1Hz. The addition of two hydroxyl groups induced a dramatic
reduction of efﬁcacy by more than 45 times for bHMM and 122
times for pHHMM. The effects of chemical maneuvers were more
pronounced at 10Hz stimulation, with an increase of IC50 values
ranging from 1.7-fold for mHM to 567-fold for pHHMM, com-
pared to mexiletine. Thus the 0.1- to 10-Hz IC50 ratio decreased
from 9.8 formexiletine to 6.3 formHMand about 2.5 for the other
compounds.
The most prominent effect of hydroxylation on the physico-
chemical properties of compounds is a reduction of the lipophilic-
ity at the experimental pH, expressed as the Log D determined
FIGURE 2 | Effects of 1mM mexiletine or hydroxylated analogs on
hNav1.4 currents. Sodium currents were recorded as described in
Figure 1.
experimentally (Table 1). The relationships of IC50 values as a
function of Log P or Log D, plotted on semilogarithmic axes, were
linearly correlated: The higher the lipophilicity, the more efﬁcient
was the compound (Figure 4). Notwithstanding, if the lipophilic-
ity was the unique factor inﬂuencing compound efﬁcacy, mHM
should have appeared less efﬁcient than it was.
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FIGURE 3 | Concentration–response relationships for mexiletine or
hydroxylated analogs on hNav1.4 channels.The curves were constructed
at 0.1 and 10Hz frequency stimulation, and ﬁtted with a ﬁrst-order binding
function (Eq. 1 in Materials and Methods). Each point is the mean±SEM
from at least three cells. The calculated IC50 values±SE of the ﬁt are reported
in Table 2. The slope factors ranged between 0.71 and 1.22.
EFFECTS OF MEXILETINE AND DERIVATIVES ON F1586C hNav1.4
MUTANT
Mexiletine is thought to bind the putative high-afﬁnity recep-
tor for LAs within the pore of sodium channels. Indeed, the
non-conservative mutation of phenylalanine to cysteine in posi-
tion 1586 (hNav1.4) within the 6th segment of domain IV dras-
tically reduced mexiletine block of inactivated channels (Desaphy
et al., 2009). The hydroxylated compounds, except mHM, were
tested on the same sodium channel mutant F1586C. Dose–
response relationships of compound effects on F1586C INa are
shown in Figure 5, and the IC50 values are reported in Table 2.
On FC channels, the compound pHM appeared as much potent
as mexiletine, whereas HMM was 2.2 times less efﬁcient, bHMM
15–20 times less, and pHHMM 20–50 times less. Compared to
WT channels, the mutation reduced sodium channel block for
all the compounds, especially at 10Hz stimulation. Indeed use-
dependence was almost abolished for mexiletine, pHM, HMM,
and bHMM, the 0.1- to 10-Hz IC50 ratio being reduced to 1.2–1.6.
In contrast, use-dependent block of F1586C mutant by pHHMM
was maintained.
EFFECTS OF MEXILETINE AND DERIVATIVES ON Y1593C hNav1.4
MUTANT
Another amino acid potentially involved in the binding of LA-
like drugs is the tyrosine in position 1593 of hNav1.4 channel
(Desaphy et al., 2010). This residue was proposed to interact with
the hydrophobic moiety of sodium channel blockers through a
π–π interaction (Ragsdale et al., 1994), although this hypothe-
sis has been recently challenged (Ahern et al., 2008). We tested
our compounds, except mHM, on the Y1593C mutant. Repre-
sentative INa current traces recorded before and after application
of 1mM mexiletine are shown in Figure 6. In contrast to WT
and F1586C channels, the Y1593C-mutant INa developed signiﬁ-
cant use-dependent reduction at 10Hz in absence of drug, ranging
from15 to 30%of control current depending on the cell. The dose–
response relationships are shown in Figure 6. To take into account
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Table 2 | Half-maximum inhibitory concentration values (IC50).
Drug Stimulation frequency WT hNav1.4 F1586C Y1593C
IC50 (μM) IC50 (μM) IC50 (μM) Imax
Mexiletine 0.1Hz 246± 15 1340± 72 476± 36 1
10Hz 24.4± 1.8 1089± 181 169± 94 0.84± 0.17
0.1-to-10Hz ratio 10.1 1.2 2.8
mHM 0.1Hz 259± 28 n.d. n.d. n.d.
10Hz 40.9± 4.7 n.d. n.d. n.d.
0.1-to-10Hz ratio 6.3 n.d. n.d.
pHM 0.1Hz 1086± 183 1132± 36 908± 30 1
10Hz 394± 82 847± 81 626± 45 0.74± 0.02
0.1-to-10Hz ratio 2.8 1.3 1.5
HMM 0.1Hz 2028± 255 2994± 74 1638± 14 1
10Hz 790± 91 2362± 187 1452± 111 0.76± 0.02
0.1-to-10Hz ratio 2.6 1.3 1.1
bHMM 0.1Hz 11883± 2992 28055± 10520 12740± 3141 1
10Hz 5190± 1021 17296± 2571 10353± 4102 0.78± 0.11
0.1-to-10Hz ratio 2.3 1.6 1.2
pHHMM 0.1Hz 30073± 7059 67730± 9125 24782± 2161 1
10Hz 13845± 2516 21056± 7650 13482± 1304 0.81± 0.03
0.1-to-10Hz ratio 2.2 3.2 1.8
These values were determined at the holding potential of −120mV from the ﬁt of concentration–response curves with the ﬁrst-order binding Eq. 1 described in
Section “Materials and Methods.”The IC50 values are given together with SE of the ﬁt. RegardingY1593C, the Imax value was ﬁxed to 1 at 0.1Hz, but was variable at
10Hz. n.d., Not determined.
the use-dependent reduction of Y1593C-mutant INa in absence of
drugs, an additional variable, namely Imax, was introduced in the
ﬁtting equation. The IC50 and Imax values are reported in Table 2.
Regarding the IC50 values at 0.1Hz, the Y1593C mutation was less
disturbing than F1586C. Compared to WT, the IC50 of mexiletine
on Y1593C INa at 0.1Hz was twofold higher, whereas no signiﬁ-
cant change was observed for the other compounds. In contrast,
the Y1593C mutation reduced dramatically use-dependent block
at 10Hz, increasing IC50 sevenfold for mexiletine, and 1.5- to 2-
fold for the other compounds, except for pHHMM. Compared
to WT, the 0.1- to 10-Hz IC50 ratio decreased to 2.8 for mexile-
tine and 1–1.5 for the other compounds. No signiﬁcant effect of
Y1593C mutation was observed for pHHMM.
MUTANT CYCLE ANALYSIS
Being modiﬁed solely on the aryloxy moiety, the derivatives of
mexiletine can be considered as simple mexiletine mutants. Thus
the combined evaluation of effects of mexiletine mutants on
hNav1.4 channel mutants allows the calculation of mutant cycles
(Hidalgo and MacKinnon, 1995; Lipkind and Fozzard, 2005). By
this way, the cross inﬂuence of one mutation on the effect of the
other can be quantiﬁed using a thermodynamic cycle in order to
characterize the intimate molecular interactions. Such a mutant
cycle analysis is illustrated for pHM in Figure 7, and coupling
energies are reported in Table 3. Since the tonic block is deter-
mined mainly by interaction of drugs with the closed channel,
mutant cycle calculation using the IC50 values for tonic block
likely reveals information about interaction of drugs with the low-
afﬁnity binding site (Figure 7A). In these conditions, the coupling
energy (ΔG) for interaction with F1586 is 1 kcal/mol,whereas ΔG
is 0.5 kcal/mol for interaction with Y1593, thereby suggesting that
mexiletine is closer to F1586 than to Y1593 in the closed channel.
Since OH substitutions reduce ΔG for F1586 but leave unchanged
ΔG forY1593,wemayhypothesize that the former amino acidmay
interact directly or indirectly with the aryloxy mexiletine moiety
whereas the latter may not be involved in low-afﬁnity binding.
On the other hand, mutant cycle calculation using the IC50 val-
ues for use-dependent block (10Hz stimulation) may allow to get
information about the interaction of drugs with the high-afﬁnity
binding site (Figure 7B). In this case, the coupling energy between
the drug and Y1593 is 0.9 kcal/mol, whereas ΔG is ∼1.8 kcal/mol
for F1586, which suggests that mexiletine may interact with both
amino acids, and that interaction with F1586 is more critical to
high-afﬁnity binding.
DISCUSSION
In this study, we used chemical maneuvers on mexiletine and site-
directed mutagenesis on hNav1.4 voltage-gated sodium channel
to get further insight in the intimate drug-channel interaction at
the LA receptor. The binding afﬁnity of LA drugs depends on the
state of the channel, being higher for the open/inactivated with
respect to the closed channel (Hille, 1977; Fozzard et al., 2011).
Please note here that tonic block measured at the stimulation of
0.1Hz results from the combination of low-afﬁnity drug binding
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FIGURE 4 | Relationship between IC50 values for drug action on
hNav1.4 channels and drug lipophilicity expressed either as Log P or
Log D.The IC50 values were determined at the holding potential of
−120mV at 0.1Hz (A) or 10Hz (B) stimulation frequency, as described in
Figure 3. The Log P and Log D values were measured as described in
Table 1. The points were linearly correlated with r 2 > 0.9.
to closed channels and, to a lesser extent, high-afﬁnity binding to
closed-state inactivated channels,while use-dependent blockmea-
sured at 10Hz stimulation depends mainly on the high-afﬁnity
binding to inactivated channels (Desaphy et al., 2001, 2004).
LIPOPHILICITY OF DRUGS IS A KEY DETERMINANT OF SODIUM
CHANNEL BLOCKADE
The results ﬁrst conﬁrm our former hypothesis (Desaphy et al.,
2003), that the presence of two hydroxyl groups on the aryloxy
moiety of LA-like drugs impedes high-afﬁnity sodium channel
blockade. We also show that the presence of a single hydroxyl
group is less deleterious, depending however on the position of
the OH group. The good correlation between the log D of com-
pounds and the IC50 values, either at 0.1 or 10Hz, suggests that
compound lipophilicity is a major parameter. Because the puta-
tive LA receptor lies within the channel pore, lipophilicitymight be
determinant allowing the compound to reach/escape its receptor
through the closed or inactivated channel. For instance, we previ-
ously showed that the drug pilsicainide,which has a negative logD,
blocks channels inactivated from the closed statewith very low efﬁ-
ciency compared to mexiletine, although afﬁnities for inactivated
channels of both drugs are comparable (Desaphy et al., 2010).
Thus altering hydrophobicity of compounds can modify drug
access to or escape from the binding site. A reduced hydropho-
bicity is expected to reduce drug access to closed channels, which
will result in a reduced apparent afﬁnity for the closed and closed-
inactivated states. Such a mechanism likely contributes signiﬁ-
cantly to the effects observed in the present study. Nevertheless,
such an explanation is not completely sufﬁcient because inhibition
of sodium current at 10Hz stimulation is greatly reduced as well
as use-dependence expressed as 0.1- to-10Hz IC50 ratio, arguing
against a trappingmechanismof themorehydrophilic compounds
within the closed/inactivated channel (O’Leary et al., 2003). This
result indicates that lipophilicity is also a critical determinant of the
intimate interaction between the compound and its receptor. We
thus tried to get more information by using contemporaneously
mexiletine analogs and sodium channel mutants.
EFFECTS OF F1586C MUTATION ON SODIUM CHANNEL BLOCKADE BY
MEXILETINE AND HYDROXYLATED DERIVATIVES
The phenylalanine in position 1586 is thought to be a key compo-
nent of LA drug binding to the LA receptor (Ragsdale et al., 1994;
Sheets et al., 2010). The aromaticity of this residue is required
for use-dependent inhibition, while its hydrophobicity may be
relevant for resting block (Li et al., 1999). By incorporating unnat-
ural ﬂuorinated phenylalanine analogs in place of the natural
phenylalanine, it was recently demonstrated that disruption of
the electrostatic potential at this position abolishes use-dependent
inhibition without affecting resting block by lidocaine and mex-
iletine (Ahern et al., 2008; Pless et al., 2011). Since the ﬂuorination
did not affect blockade by the neutral benzocaine, the authors
concluded that a π–cation interaction between phenylalanine side
chain and the charged amineof drugs is a keyplayer inhigh-afﬁnity
binding, at least for class Ib antiarrhythmics such as mexiletine
(Pless et al., 2011). Accordingly, we observed that the mutation
of F1586 by a non-aromatic cysteine nearly zeroed use-dependent
inhibition by mexiletine and its derivatives, except pHHMM. In
addition, we found that low-afﬁnity block by mexiletine was also
lightly affected by F1586C, because the IC50 value calculated at
0.1Hz stimulation was 50% greater than mexiletine afﬁnity for
WT channels in the closed state (∼800μM, Desaphy et al., 2001).
Interestingly, the inhibition of F1586C by pHM and mexile-
tine was comparable, indicating that the presence of one hydroxyl
group in pHM mainly reduced high-afﬁnity, use-dependent block
of WT channels (as in mHM). Considering the π–cation interac-
tion with F1586 as the main determinant of high-afﬁnity binding,
this suggests that alteration of the aryloxy moiety by introduc-
tion of the OH in mHM and pHM is able to weaken the critical
interaction of the charged amine with F1586, through a mecha-
nism resembling cooperativity between twopharmacophores.Our
results suggest that this may be related to the reduction of drug
lipophilicity (see Log D value in Table 1). Nevertheless, it has been
recently shown that addition of a methyl group in para position
of lidocaine is also able to weaken the π–cation interaction with
F1586 (see supplemental data in Pless et al., 2011), suggesting that
changes other than lipophilicity may be also involved. As hypoth-
esized from previous experiments using aryloxy-substituted mex-
iletine analogs (Franchini et al., 2003), a possibility is that the
presence of substituents on the aromatic ring may slightly modify
the orientation of the molecule, thereby weakening the π–cation
interaction. It is also interesting that while the overall hydropho-
bicity does not change between mHM and pHM, the IC50 for
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FIGURE 5 | Concentration–response relationships for hydroxylated
mexiletine analogs on F1586C hNav1.4 channel mutants.The curves were
constructed at 0.1 and 10Hz frequency stimulation, and ﬁtted with a
ﬁrst-order binding function (Eq. 1 in Materials and Methods). Each point is the
mean±SEM from at least three cells. The calculated IC50 values±SE of the
ﬁt are reported in Table 2. The slope factors ranged between 0.74 and 1.11.
use-dependent block of WT channels decreases 10-fold with the
OH in para position, thereby conﬁrming that not only lipophilicity
is involved. Thus, in function of its position, the substituent may
modify more or less the orientation of the entire molecule within
the binding site. It is possible to appreciate from Figure 8 how OH
addition in meta have limited effects on aryloxy hindrance and on
electrostatic distribution within the aryloxy (compared to mexile-
tine), whereas the OH in para concentrates more electronegativity
close to the molecule extremity and induces a major steric hin-
drance. We may speculate that, in case of π–π stacking between
the aryloxy and Y1593 side chain (see below), the OH in para
position as in pHM may interact very negatively with the OH in
Y1593, whereas the OH in meta position may be less unfavorable.
The former negative interaction may result from steric hindrance
or local electrostatic repulsion between the two OH.
When the strong interaction between the charged amine group
and F1586 is disrupted by cysteine substitution, pHM has nearly
the same activity than mexiletine even if it displays a reduced
Log D. This latter observation suggests that an additional OH,
as in mHM and pHM, or substitution of F1586 have no additive
effect on low-afﬁnity binding. Such an observation would be in
accord with the proposed horizontal orientation of LA drugs in
the closed channel, where the aromatic moiety of drugs may be
exposed toward F1586 (Bruhova et al., 2008; Hanck et al., 2009;
Sheets et al., 2010). Thus the alteration of one or the other may
determine similar effect on low-afﬁnity binding.
Interestingly,wenoted thatmHMandpHMshowan electrosta-
tic potential similar to that of mexiletine (Figure 8). In additionwe
calculated the value of energy coupling for tonic block calculated
from mexiletine/pHM and F1586C mutants cycle, which resulted
close to 1 kcal/mol (Table 3), being in the range expected for a
through-space electrostatic coupling (Hidalgo and MacKinnon,
1995). Altogether, these results suggest that the aromatic moiety of
the drugmay interact with F1586 in the closed channel throughπ–
π stacking thereby accounting for low-afﬁnity binding. It should
be noted however that, in contrast with this hypothesis, the varia-
tion of F1586 electrostatic potential by ﬂuorination was shown to
have no effect on low-afﬁnity binding of lidocaine (Ahern et al.,
2008). Thus an alternative hypothesis to be considered may be an
indirect effect of F1586C mutation, through an allosteric mech-
anism, on the electrostatic coupling between the aryloxy drug
moiety and another aromatic residue in the closed pore.
Regarding HMM and bHMM, a similar impairment of positive
cooperativity between the aromatic and protonable drug extrem-
ities may account for the reduction of high-afﬁnity blockade of
WT channels, and use-dependent block was also nearly zeroed by
the F1586C mutation. Moreover, tonic block of WT channels by
HMM and bHMM was greatly reduced compared to that exerted
by mexiletine. Thus the IC50 values for tonic block by HMM and
bHMM were more than 2- and 10-fold higher than the speciﬁc
afﬁnity of mexiletine for closed channels, respectively (∼800μM,
Desaphy et al., 2001), indicating that these compounds signiﬁ-
cantly affect the low-afﬁnity binding. Interestingly, we observed
that the electrostatic potentials of the aryloxy moiety of HMM
and bHMM were 10-kcal/mol more negative than that of mexile-
tine, mHM, and pHM. We may thus hypothesized that alteration
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FIGURE 6 | Concentration–response relationships for mexiletine and
hydroxylated analogs onY1593C hNav1.4 channel mutants. (A)
Representative sodium current traces recorded in a HEK293 cell
permanently transfected withY1593C hNav1.4 mutant, by depolarizing the
cell to −30mV from an holding potential of −120mV at 0.1 and 10Hz
stimulation frequency, before and during application of 1mM mexiletine.
Note the use-dependent current reduction in absence of drug. (B–F)The
concentration–response relationships were constructed at 0.1 and 10Hz
frequency stimulation, and ﬁtted with a ﬁrst-order binding function (Eq. 1 in
Materials and Methods). Each point is the mean±SEM from at least three
cells. The calculated IC50 and Imax values±SE of the ﬁt are reported in
Table 2. The slope factors ranged between 0.69 and 1.76.
of electrostatic coupling may contribute to weaken the interaction
of the aromatic tail of HMM/bHMM with the low-afﬁnity recep-
tor. Such a hypothesis is supported by the low energy coupling
value (<1 kcal/mol) for tonic block by HMM and bHMM. Most
probably, other parameters, including hydrophobicity, should be
however involved to explain the large difference in tonic block
exerted by HMM and bHMM. In addition, we observed that both
HMM and bHMM exert a lower tonic block of F1586C channel
with respect to mexiletine and pHM, indicating that substituents
on HMM and bHMM have additional effects to those resulting
from the suppression of aromatic side chain at position 1586.
The compound pHHMM shows an electrostatic potential sim-
ilar to HMM/bHMM, and tonic block was similarly reduced
twofold by F1586C. Quite surprisingly, the mutation had no sig-
niﬁcant effect on pHHMM use-dependence, indicating that the
drug does not bind to F1586 at all. This latter observation suggests
that F1586 is no more involved in the higher-afﬁnity binding of
pHHMM.
FIGURE 7 | Mutant cycle analysis of mexiletine and pHM binding to
the wild-type hNav1.4 channel and its mutantsY1593C and F1586C.
Mutant cycle analysis for tonic block considers IC50 values calculated at
0.1Hz stimulation frequency (A), while IC50 calculated at 10Hz stimulation
frequency allowed mutant cycle analysis for use-dependent block (B). The
Xi andYi values represent the changes in afﬁnity with each mutation,
calculated as the ratio of IC50 values. The coupling constant Ω is calculated
as the X 1 to X 2 ratio and the coupling energy ΔG is calculated as RT ·ln Ω,
where R is the perfect gas constant (8.314 JKmol−1) andT the temperature
expressed in Kelvin (295.15K= 22˚C). The calculated ΔG shown in red was
converted to kilocalorie per mole.
Table 3 | Coupling energy (ΔG, kcal/mol) calculated from mutant
cycles, as shown in Figure 7.
Drug Tonic block Use-dependent block
F1586 Y1593 F1586 Y1593
pHM 0.97 0.49 1.79 0.87
HMM 0.75 0.50 1.60 0.78
bHMM 0.49 0.35 1.53 0.73
pHHMM 0.52 0.50 2.00 1.15
EFFECTS OF Y1593C MUTATION ON SODIUM CHANNEL BLOCKADE BY
MEXILETINE AND HYDROXYLATED DERIVATIVES
The tyrosine in position 1593 was originally individuated as an
important component of the intimate drug-receptor interaction,
possibility through hydrophobic interaction with the aromatic
moiety of LA drugs (Ragsdale et al., 1994). This hypothesis has
been somewhat challenged because Y1593 mutations can mod-
ify sodium channel gating, which rends difﬁcult the interpreta-
tion of pharmacological results. In addition to various effects on
steady-state activation and inactivation, a slowing of recovery from
inactivation has been reported (O’Reilly et al., 2000; Xiao et al.,
2001), which may explain the use-dependent reduction of Y1593C
currents we observed in the absence of drug. Recently, the contri-
bution of Y1593 to π–cation or π–π interactions with lidocaine
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FIGURE 8 | Calculation of drug electrostatic potential. Mexiletine and its
hydroxylated analogs are displayed as chemical structures presenting in bold
the moiety studied by ab initio calculations (upper panels). For each
compound, both the corresponding HF/3-21G∗ minimized three-dimensional
structure and the electrostatic potential map is given in equatorial and lower
panels, respectively. For each moiety, the scale bar indicates the electrostatic
potential surface value range in kilocalorie per mole, the negative value being
the one used in structure–activity evaluations. The HMM, bHMM, and
pHHMM moieties (lower half of the ﬁgure) presented the most negative
electrostatic potential values (around −65 kcal/mol), which most likely may
allow less favorable interactions with electron-rich aromatic rings (e.g., F1586
orY1593 rings), compared to the ones expected for Mex, mHM, and pHM
moieties with a less negative electrostatic potential (around −50 kcal/mol).
The Log D values experimentally measured at pH 7.4 are indicated.
has been ruled out by experiments using ﬂuorinated amino acids
(Ahern et al., 2008).
As for pilsicainide in a previous study (Desaphy et al., 2010),
we observed that Y1593C reduced use-dependent sodium current
blockade by mexiletine but to a lesser extent than F1586C.
The mutation may impede a direct interaction of Y1593 with
the drug, or reduce the lipophilicity in proximity of the binding
site. Thus considering Y1593 being involved either directly or
indirectly on mexiletine binding, its mutation to C1593 may coop-
eratively reduce the strong interaction between the charged amine
and F1586. The Y1593C mutation had a similar effect on mex-
iletine derivatives (except pHHMM), reducing use-dependence
without altering tonic block. This observation indicates thatY1593
is not involved in the low-afﬁnity binding, still in accord with
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FIGURE 9 | Synopsis of possible interactions of mexiletine and
hydroxylated analogs with the low (A) and high (B) binding site within
the wild-type hNav1.4 channel and its mutants F1586C and Y1593C. (A)
Regarding the low-afﬁnity binding to closed channels, our results are in accord
with an horizontal orientation of the drug, with the aryloxy moiety interacting
either directly or indirectly with F1586 through electrostatic coupling. The
addition of OH groups as in mHM and pHM does not modify aryloxy
electrostatic potential thereby leaving this interaction unaltered. The F1586C
mutation weakens interaction with Mex, mHM, and pHM to the same extent
(arrow 1). Introduction of OH as in HMM and bHMM weakens the interaction
due to modiﬁcation of aryloxy electrostatic potential and possibly other
parameters (arrow 2). The F1586C mutation produces additional weakening of
the interaction with HMM and bHMM (arrow 3). Finally theY1593C mutation
has no effect on low-afﬁnity binding (not illustrated). (B) Regarding the
high-afﬁnity binding to inactivated channels, addition of OH groups to the
aryloxy moiety cooperatively reduced the interaction of charged amine group
with F1586 (arrow 1). The amplitude of this effect depends on the OH position
and lipophilicity. The F1586C mutation disrupts the π–cation interaction, so
that OH substitutions have no more inﬂuence on binding (arrow 2 and 3). In
contrast, theY1593C mutation impairs only partially the π–cation interaction
of mexiletine through cooperativity (arrow 4). The mutation also further
impairs the binding of hydroxylated analogs (arrow 5).
the proposed position of LA drugs in the closed channel (Sheets
et al., 2010). Tonic block and use-dependence of pHHMM was not
altered by Y1593C, most probably because hydrophobicity is no
more critical for a drug having a very negative Log D.
SYNOPSIS
We made an attempt to summarize the main ﬁndings in a graph-
ical sketch (Figure 9). Regarding the low-afﬁnity binding to
closed channels (Figure 9A), our results suggest that the ary-
loxy moiety of drugs may interact either directly or indirectly
with F1586 and suggest that electrostatic coupling is critical in
drug binding. Regarding the high-afﬁnity binding to inactivated
channels (Figure 9B), addition of OH groups on the aryloxy moi-
ety cooperatively reduced the interaction of drug charged amine
group with F1586. The amplitude of this effect depends mainly on
lipophilicity and also on the position of the OH substituent.
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